Tracked deals
7
7 tracked deals across 2019-2023.
Operating Company
Healthcare
Discovery Life Sciences
Huntsville, Alabama, United States
Discovery Life Sciences provides highly characterized human biospecimens and cellular starting materials integrated with multi-omic analytical services to advance cell and gene therapy and precision medicine programs.
- Focus Areas
- Biospecimen procurement and biobanking, Biomarker services, Multi-omics analytics
- Website
- dls.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
5 buyout · 1 addon · 1 divestiture
Discovery Life Sciences Acquisition Volume by Year
Last 5 years
Supporting Data
Recent Transactions
-
April 11, 2023
- Buyer
- Discovery Life Sciences
- Target
- ReachBio Research Labs
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
July 12, 2022
- Buyer
- Discovery Life Sciences
- Target
- AllCells
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.
-
- Buyer
- Discovery Life Sciences
- Target
- Gentest (business unit of Corning Incorporated)
- Seller
- Corning Incorporated
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Divestiture
Discovery Life Sciences has acquired the Gentest business unit from Corning Incorporated to expand its in vitro ADME and toxicology reagent and services offering. The deal complements Discovery’s recent acquisition of In Vitro ADMET Laboratories (IVAL) and strengthens its hepatocyte, microsome and ADME-related product and contracted research capabilities for pharmaceutical and life sciences customers.
-
December 2, 2021
- Buyer
- Discovery Life Sciences
- Target
- In Vitro ADMET Laboratories (IVAL)
- Industry
- Healthcare Services
- Location
- Maryland, United States
- Type
- Buyout
Discovery Life Sciences has acquired Maryland-based In Vitro ADMET Laboratories (IVAL) to add the world’s largest hepatocyte inventory and leading in vitro ADMET expertise. IVAL founder Albert P. Li, Ph.D. will join Discovery as Chief Scientific Officer of Pharmacology and Toxicology as Discovery expands its biospecimen and biomarker service capabilities to better support drug metabolism, toxicology, and pharmacology testing for pharma customers.
-
- Buyer
- Discovery Life Sciences
- Target
- Targos Molecular Pathology GmbH
- Industry
- Healthcare Services
- Location
- Hesse, Germany
- Type
- Addon
Discovery Life Sciences has acquired Targos Molecular Pathology GmbH, a leading European molecular pathology laboratory, to expand its global tissue biomarker services. The deal integrates Targos's IHC and clinical-pathology capabilities with Discovery's North American labs and HudsonAlpha Discovery sequencing/bioinformatics capabilities to create a market-leading global tissue biomarker services division.
-
November 9, 2020
- Buyer
- Discovery Life Sciences
- Target
- East West Biopharma
- Industry
- Healthcare Services
- Location
- Kyiv, Ukraine
- Type
- Buyout
Discovery Life Sciences acquired East West Biopharma, a European human biospecimen contract research organization with a large biocollection network in Ukraine. The deal expands Discovery’s biospecimen collection and clinical site footprint across Europe, strengthening its global position as a leading provider of biospecimen and related scientific services.
-
- Buyer
- Discovery Life Sciences
- Target
- QualTek Molecular Laboratories
- Industry
- Healthcare Services
- Location
- United States
- Type
- Buyout
Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.
Related Acquisition Pages
Healthcare Services Buyers & Acquisitions
4 tracked deals by Discovery Life Sciences.
Biotechnology Buyers & Acquisitions
3 tracked deals by Discovery Life Sciences.
Acquisitions in California
1 tracked deal by Discovery Life Sciences.
Acquisitions in Maryland
1 tracked deal by Discovery Life Sciences.
Acquisitions in Massachusetts
1 tracked deal by Discovery Life Sciences.
Acquisitions in Washington
1 tracked deal by Discovery Life Sciences.
Selling a company? Get in front of buyers like Discovery Life Sciences
Turn tracked acquisition activity into an outreach-ready buyer list.